Abstract

A recombinant form of the high affinity, natural inhibitor of tumour necrosis factor α (TNFα) is currently under development for the treatment of rheumatoid arthritis (RA).1 This molecule is referred...

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title
Journal
Date
Author
FRI0059 The efficacy and safety of pegylated recombinant methionyl human soluble tumour necrosis factor receptor type i (peg stnf-ri; p55) in a randomised, placebo-controlled, clinical study of patients with rheumatoid arthritis (ra)
M Macri ... D Furst
-
M Macri, et. al.M Macri ... D Furst
01 Jun 2001
Design of PEGylated soluble tumor necrosis factor receptor type I (PEG sTNF-RI) for chronic inflammatory diseases
Carl K Edwards
Advanced Drug Delivery Reviews | VOL. 55
Carl K EdwardsCarl K Edwards
12 Sep 2003
Combination benefit of treatment with the cytokine inhibitors interleukin-1 receptor antagonist and PEGylated soluble tumor necrosis factor receptor type I in animal models of rheumatoid arthritis.
Elizabeth S Chlipala ... Jon Scherrer
Arthritis and rheumatism | VOL. 43
Elizabeth S Chlipala, et. al.Elizabeth S Chlipala ... Jon Scherrer
01 Dec 2000
Influence of dose, dose interval and administration route of recombinant human soluble tumour necrosis factor receptor type I on orthodontic tooth movement in rats
Xiuna Hao ... Yongmei Hua
Archives of Oral Biology | VOL. 56
Xiuna Hao, et. al.Xiuna Hao ... Yongmei Hua
25 Jun 2011
View more papers

More From: Annals of the Rheumatic Diseases

Paper Title
Journal
Date
Author
The associations between poorer pain-related health status and increased hospitalisations and excess mortality in patients with rheumatoid arthritis (RA): a prospective cohort analysis using the Australian Rheumatology Association Database (ARAD)
Huai Leng Pisaniello ... Samuel Lawrance Whittle
Annals of the Rheumatic Diseases | VOL. -
Huai Leng Pisaniello, et. al.Huai Leng Pisaniello ... Samuel Lawrance Whittle
29 May 2024
Integrated safety analysis of filgotinib in patients with moderate-to-severe rheumatoid arthritis over a treatment duration of up to 8.3 years
Gerd R Burmester ... Daniel Aletaha
Annals of the Rheumatic Diseases | VOL. -
Gerd R Burmester, et. al.Gerd R Burmester ... Daniel Aletaha
23 May 2024
BCMA-CD19 compound CAR T cells for systemic lupus erythematosus: a phase 1 open-label clinical trial
Weijia Wang ... Yong Yuan
Annals of the Rheumatic Diseases | VOL. -
Weijia Wang, et. al.Weijia Wang ... Yong Yuan
22 May 2024
Exploring the effect on primary endpoints in trials testing targeted therapy interventions for rheumatoid arthritis: a meta-epidemiological study on the appropriate use of a core outcome set
Philip Rask Lage-Hansen ... Robin Christensen
Annals of the Rheumatic Diseases | VOL. -
Philip Rask Lage-Hansen, et. al.Philip Rask Lage-Hansen ... Robin Christensen
22 May 2024
View more papers